Rob Cerwinski, a partner in Goodwin's IP Litigation group, helps lead the firm’s industry-leading biosimilars practice group and has extensive experience litigating intellectual property disputes concerning pharmaceutical, biosimilar, and other biologic drug products. For over 20 years, Mr. Cerwinski has represented clients such as Teva, Actavis, Celltrion, Fresenius, Lupin, Sun, Dr. Reddy’s, and Cipla in patent and trade secret litigation before federal and state courts across the country, and before the U.S. Patent & Trademark Office.. Mr. Cerwinski also co-founded Goodwin’s award-winning biosimilars blog www.bigmoleculewatch.com.

Mr. Cerwinski brings to his practice an exceptional combination of patent law expertise and technical proficiency in the pharmaceutical and biotechnology fields. He holds a graduate degree in cellular and molecular biology, and before pursuing a career in law, he worked for a major Japanese pharmaceutical company in Tokyo assisting with intellectual property matters concerning biotechnology products.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Mr. Cerwinski’s recent work includes representing:

  • Celltrion in BPCIA litigation concerning Celltrion’s biosimilar to Herceptin. Genentech v Celltrion (D. Del.)
  • Celltrion in BPCIA litigation concerning Celltrion’s biosimilar to Rituxan. Genentech v Celltrion (D.N.J.)
  • Actavis in Hatch-Waxman patent infringement litigation concerning Actavis’s generic equivalent to Noxafil®, an antibiotic. A favorable settlement was obtained after trial. Merck v. Fresenius (D. Del.)
  • Dr. Reddy’s in Hatch-Waxman patent infringement litigation concerning DRL’s generic equivalent to Suboxone®, an anti-addiction product. A judgment of non-infringement was obtained after trial. Indivior v. DRL (D. Del.)
  • Fresenius in Hatch-Waxman patent infringement litigation concerning Fresenius’s generic equivalent to Cubicin®, an antibiotic. A favorable settlement was obtained before trial. Cubist v. Fresenius (D. Del.)
  • Actavis in Hatch-Waxman patent infringement litigation concerning Actavis’s generic equivalent to Staxyn®, an ED medication. A judgment of patent invalidity was obtained after an appeal to the Federal Circuit. Bayer v. Actavis (D. Del.)
  • Teva in Hatch-Waxman patent infringement litigation concerning Teva's generic equivalent to Pfizer's Atelvia®, an osteoporosis medication. Warner Chilcott v. Teva Pharmaceuticals (D.N.J.)
  • Teva in Hatch-Waxman patent infringement litigation concerning Teva's generic equivalent to Pfizer's Neurontin®, an epilepsy medication. A favorable settlement was obtained during jury trial. Warner-Lambert v. Teva Pharmaceuticals (D.N.J.)
  • Teva in Hatch-Waxman litigation concerning Teva's generic equivalent to OxyContin®, an opioid pain medication. A favorable settlement was obtained prior to trial. Purdue Pharma v. Teva Pharmaceuticals (S.D.N.Y.)
  • Teva in a patent infringement action concerning Teva's generic equivalent to Biaxin®, an antibiotic. A favorable settlement was obtained while summary judgment motion was pending. Abbott Laboratories v. Teva Pharmaceuticals (N.D. Ill.)
  • Teva in patent infringement action concerning Teva's generic equivalent to Biaxin XL®, an antibiotic. A favorable settlement was obtained after the Federal Circuit vacated a preliminary injunction. Abbott Laboratories v. Teva Pharmaceuticals (N.D. Ill.)
  • Teva in a patent infringement action concerning Teva's generic equivalent to Augmentin®, an antibiotic. Seven patents were invalidated in two summary judgment motions and a bench trial. Teva Pharmaceuticals v. GlaxoSmithKline (E.D. Va.)
  • Teva in a patent infringement action involving Teva's equivalent to Wellbutrin®, an antidepressant. A favorable settlement was obtained. Glaxo Wellcome v. Teva Pharmaceuticals (D. Del.)
  • Teva in Hatch-Waxman litigation concerning Teva's equivalent to Zithromax®, an antibiotic. A favorable settlement was obtained while summary judgment motions were pending. Teva Pharmaceuticals v. Pfizer (S.D.N.Y.)
  • Breckenridge in a patent infringement action involving Breckenridge's sulfatol acne medication. A favorable settlement was obtained. Bradley Pharmaceuticals v. Breckenridge Pharmaceutical (D.N.J.)
  • Teva in Hatch-Waxman litigation concerning generic equivalents to Allegra® and Allegra-D 12 Hour® allergy medications. The case settled after a preliminary injunction was denied and summary judgments of non-infringement and invalidity were obtained. Aventis and AMR v. Teva Pharmaceuticals (D.N.J.)
  • Estée Lauder in a patent infringement litigation concerning cosmetic emulsions. A favorable settlement was obtained. Revlon v. Estée Lauder (S.D.N.Y.)
  • Faulding in patent infringement litigation concerning Cardizem CD®, a hypertension medication. A favorable settlement was obtained. Hoechst Marion Roussel v. Faulding (D.N.J.)
  • American Home Products and Takeda Chemical Industries in a patent infringement litigation concerning acellular pertussis vaccines. Summary judgment of non-infringement was obtained. Evans Medical v. American Cyanamid (S.D.N.Y.)
Professional Activities

Mr. Cerwinski is a member of the New York City Bar Association, the New York State Bar Association, the New York Intellectual Property Law Association, the American Intellectual Property Law Association and the American Bar Association.

Professional Experience

Prior to joining Goodwin in 2014, Mr. Cerwinski was a partner at Kenyon & Kenyon in New York City.

Recognition

Mr. Cerwinski was named by IAM Patent 1000 – The World’s Leading Patent Professionals 2017 as one of the world’s leading patent litigators.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 1997
Boston University School of Law
(cum laude)
M.S., Cellular and Molecular Biology, 1993
Roswell Park Cancer Institute
B.S., Biology, 1991
Rensselaer Polytechnic Institute

Admissions

Bar

New York

Courts

U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
Get In Touch
German Translation
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师